Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-2 phase 3 trial of SAR442168 versus teriflunomide in relapsing multiple sclerosis
MOH_2020-09-22_009241Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tolebrutinib in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoints: Confirmed disability worsening over 6 months, Annualized relapse rate and 1 more. Started Sep 2020; status: recruiting.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2020-09-22_009241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-22_009241.